Please assess the completion status of the following clinical trial:

Trial Title: Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a histologically confirmed diagnosis of a lymphoid malignancy expressing the cluster of differentiation (CD)20 antigen and have failed at least one prior standard systemic therapy~* Patients must have evidence of persistent lymphoma by physical examination, radiographic studies, bone marrow evaluation, flow cytometry, or polymerase chain reaction (PCR)~* Creatinine \< 2.0~* Bilirubin \< 1.5 mg/dL~* Patients must have an expected survival of \> 60 days and must be free of major infection including human immunodeficiency virus (HIV)~* Patients must have an HLA-identical related or unrelated donor~* DONOR: Donor eligibility includes both HLA-matched relatives or HLA matched, unrelated volunteer donors; related donors should be matched by molecular methods at the intermediate resolution level at HLA-A, B, C, and DRB1 according to FHCRC Standard Practice Guidelines and to the allele level at DQB1; unrelated donors should be identified using matching criteria that follows the FHCRC Standard Practice Guidelines limiting the study to eligible donors that are allele matched for HLA-A, B, C, DRB1, and DQB1 (Grade1), and accepting up to one allele mismatch as per Standard Practice Grade 2.1 for HLA-A, B, or C~* Donor must consent to granulocyte colony-stimulating factor (G-CSF) (filgrastim) administration and leukapheresis~* Donor must have adequate veins for leukapheresis or agree to placement of central venous catheter (femoral, subclavian)~Exclusion Criteria:~* Systemic anti-lymphoma therapy given in the previous 30 days~* Patients who have experienced progressive disease within 3 months of prior Bexxar or Zevalin~* Inability to understand or give an informed consent~* Central nervous system lymphoma~* Pregnancy~* Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment~* Southwest Oncology Group (SWOG)/Eastern Cooperative Oncology Group (ECOG) performance score \> 2~* Eligible for radioimmunotherapy-based autologous transplant trial~* Medical condition that would contraindicate allogeneic transplantation~* Evidence of Human Anti-Mouse Antibody (HAMA) for patients with prior exposure to therapeutic murine antibodies~* Eligible for other therapeutic options that will be more likely to have a better long-term disease-free survival with lower potential toxicity (e.g., non-transplant therapy, autologous transplants, etc.) than this study~* Other grave medical conditions considered to represent contraindications to bone marrow transplant (BMT) (e.g. unstable angina, pulmonary dysfunction \[diffusing capacity of the lung for carbon monoxide (DLCO) \< 30%, total lung capacity (TLC) \< 30%, continuous supplemental oxygen\], acquired immune deficiency syndrome \[AIDS\], etc.)~* DONOR: Identical twin~* DONOR: Age less than 12 years~* DONOR: Pregnancy~* DONOR: Infection with HIV~* DONOR: Inability to achieve adequate venous access~* DONOR: Known allergy to G-CSF~* DONOR: Current serious systemic illness or infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (90Y ibritumomab tiuxetan, hematopoietic transplant) (Type: EXPERIMENTAL): See Detailed Description

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete